Volume Plays: ViroPharma, Stec - TheStreet

NEW YORK (

TheStreet

) -- Several stocks trading near $10 were moving on above-average volume during Wednesday's session.

ViroPharma

(VPHM)

stock jumped 5.8% to $11.20 after raising its 2010 sales expecations for its Cinryze drug for the prevention of hereditary angioedema attacks. ViroPharma now expects Cinryze sales of between $150 to $175 million compared with its previous prediction of $145 million to $165 million.

The 50-day average daily volume for ViroPharma is about 969,900.

Stec

(STEC)

stock fell 24.9% to $ 10.10 after the company reported that it expects first quarter 2010 revenue to be in the range of $33 million to $35 million and non-GAAP loss per share to be in the range of 11 cents to 13 cents. The Street expected earnings of 20 cents a share for Stec, on revenue of $70.16 million.

Stec believes that the first half of 2010 will be a trough period for its business due to an inventory carryover by its largest customer. The 50-day average daily volume for Stec is about 5.4 million.

Verigy

( VRGY) stock lost 5% at $10.30 after the company predicted weaker-than-expected earnings. Verigy is providing revenue outlook in the range of $107 million to $117 million and loss per share on a GAAP basis in the range of 3 to 12 cents. Furthermore, Verigy expects non-GAAP earnings per share, excluding charges to be in the range of an 8 cent loss to a penny gain. Analysts had arrived at a consensus forecast of 2 cents on revenue of $117.4 million.

Verigy believes that it will return to profitability in the third quarter. The 50-day average daily volume for Verigy is about 724,400.

-- Reported by Andrea Tse in New York

Check out high-volume, under-$10 stocks at the Dollar Store

>>See our new stock quote page.

Follow TheStreet.com on

Twitter

and become a fan on

Facebook.

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.